Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Oligodendroglioma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Head and Neck Neoplasms 1Gliosarcoma 1

Interventions

tofacitinib 6ibrutinib 6Imatinib Mesylate 5ofatumumab 4Rituximab 4nilotinib 3ruxolitinib 2bosutinib 2asciminib 2Pentostatin 2Oxycodone 2Naloxone 2KW-2478 2Dasatinib 2ziconotide 1sodium luminolate 1posaconazole 1pegfilgrastim 1oblimersen 1obinutuzumab 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1fenebrutinib 1canakinumab 1baricitinib 1abexinostat 1Voriconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bronchiolitis Obliterans Syndrome × lonafarnib × Clear all
NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡